With a compound annual growth rate (CAGR) of 3.3%, the chemotherapy-induced myelosuppression treatments industry is predicted to grow from its current value of US$ 8.06 billion in 2022 to a valuation of US$ 9.78 billion by 2028. A new study by FMI reveals that the chemotherapy-induced myelosuppression treatment market is expected to grow at a …